Franchette W.P.J. van den Berkmortel

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer et al. · The Lancet Oncology · 2017 · 158 citations

Medicine, Endocrinology, Pharmacology +14

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands

Anouk Jochems, Maartje G. Schouwenburg, B Leeneman et al. · European Journal of Cancer · 2016 · 107 citations

Medicine, Oncology, Surgery +16

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Olivier J. van Not, Rik J. Verheijden, Alfonsus Johannes Maria van den Eertwegh et al. · JAMA Oncology · 2022 · 106 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17